These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31021848)

  • 21. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.
    Murrough JW; Collins KA; Fields J; DeWilde KE; Phillips ML; Mathew SJ; Wong E; Tang CY; Charney DS; Iosifescu DV
    Transl Psychiatry; 2015 Feb; 5(2):e509. PubMed ID: 25689570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
    Tan A; Costi S; Morris LS; Van Dam NT; Kautz M; Whitton AE; Friedman AK; Collins KA; Ahle G; Chadha N; Do B; Pizzagalli DA; Iosifescu DV; Nestler EJ; Han MH; Murrough JW
    Mol Psychiatry; 2020 Jun; 25(6):1323-1333. PubMed ID: 30385872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
    Hartberg J; Garrett-Walcott S; De Gioannis A
    Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acupuncture treatment modulates the corticostriatal reward circuitry in major depressive disorder.
    Wang Z; Wang X; Liu J; Chen J; Liu X; Nie G; Jorgenson K; Sohn KC; Huang R; Liu M; Liu B; Kong J
    J Psychiatr Res; 2017 Jan; 84():18-26. PubMed ID: 27693978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychopharmacol; 2019 Apr; 33(4):494-501. PubMed ID: 30789302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression.
    Lin C; Karim HT; Pecina M; Aizenstein HJ; Lenze EJ; Blumberger DM; Mulsant BH; Kharasch ED; Reynolds Iii CF; Karp JF
    Neuroimage Clin; 2019; 21():101679. PubMed ID: 30685701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
    Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
    Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.
    Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA
    Neuroimage Clin; 2018; 20():92-101. PubMed ID: 30094160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Ketamine in Severe Depression with suicidal ideation - Insights from a Case Study.
    Gurnani T; Khurshid KA
    Asian J Psychiatr; 2017 Oct; 29():112-113. PubMed ID: 29061405
    [No Abstract]   [Full Text] [Related]  

  • 34. Trait anhedonia is associated with reduced reactivity and connectivity of mesolimbic and paralimbic reward pathways.
    Keller J; Young CB; Kelley E; Prater K; Levitin DJ; Menon V
    J Psychiatr Res; 2013 Oct; 47(10):1319-28. PubMed ID: 23791396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.
    Salvadore G; Cornwell BR; Sambataro F; Latov D; Colon-Rosario V; Carver F; Holroyd T; DiazGranados N; Machado-Vieira R; Grillon C; Drevets WC; Zarate CA
    Neuropsychopharmacology; 2010 Jun; 35(7):1415-22. PubMed ID: 20393460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
    Zhou YL; Wu FC; Wang CY; Zheng W; Lan XF; Deng XR; Ning YP
    J Affect Disord; 2020 Nov; 276():608-615. PubMed ID: 32871692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural correlates of suicidal ideation and its reduction in depression.
    Ballard ED; Lally N; Nugent AC; Furey ML; Luckenbaugh DA; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25550331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits.
    Ossewaarde L; Verkes RJ; Hermans EJ; Kooijman SC; Urner M; Tendolkar I; van Wingen GA; Fernández G
    Biol Psychiatry; 2011 Sep; 70(6):568-74. PubMed ID: 21601833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.